ARIAD Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Jan 2, 2001
- CIK
- 0000884731
- Similar Companies
- Business
- ARIAD Pharmaceuticals, Inc. (ARIA) develops and commercializes small-molecule therapeutics for the treatment of cancer and rare diseases. The company focuses on targeted protein kinase inhibitors and other innovative oncology drugs; its lead product, Iclusig (ponatinib), treats adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to prior tyrosine kinase inhibitor therapy; earlier pipeline candidates included brigatinib for non-small cell lung cancer (NSCLC) and other investigational compounds targeting specific genetic mutations. ARIAD operates primarily in the biopharmaceutical industry, serving oncologists, hematologists, and patients worldwide through partnerships with distributors and collaborators. Founded in 1991 and headquartered in Cambridge, Massachusetts, the company expanded geographically to Europe and Asia via regulatory approvals and commercialization alliances [ from prior searches, adjusted for knowledge]. In 2017, ARIAD was acquired by Takeda Pharmaceutical Company Limited in a $5.2 billion deal, marking a significant strategic shift as Takeda integrated ARIAD's oncology portfolio into its global operations; post-acquisition, Iclusig commercialization continued under Takeda's oversight with expanded label indications and manufacturing enhancements. Recent developments include Takeda's ongoing advancements in Iclusig formulations and combination therapies announced in 2024-2025 clinical updates, alongside no major standalone changes for ARIAD as an independent entity since the acquisition. The company now functions as part of Takeda's U.S.-based oncology subsidiary structure, with no recent name changes, funding rounds, or new product launches under the ARIA ticker, which ceased trading post-merger [ from prior].
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
Braiin Launches Agentic AI Workforce ARIA to Capture the US$32.0 Billion Global Real Estate Software Market by 2033
CoreWeave ARIA Launches as an AI Research and Iteration Agent with autonomous research and collaborative intelligence
ARIA Cybersecurity Announces a Leading Pet Food Producer Deploys AZT PROTECT(TM)
ARIA Cybersecurity Announces Major Oil Refiner Deploys AZT PROTECT(TM)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
ARIA Resort & Casino and JKS Restaurants Unveil Gymkhana, Bringing Indian Fine Dining to the Las Vegas Strip for the First Time
ARIA Cybersecurity Adds Features To Expand AZT PROTECT(TM) Into the Embedded IIOT Market
ARIA Cybersecurity Secures Midwest Manufacturer's Critical Systems with Managed AZT PROTECT(TM) Service Deployment
ARIA Cybersecurity Protects Large US Steel Mills from Cyberattacks
Gymkhana to Debut at ARIA Resort & Casino in Las Vegas This Fall
ARIA Cybersecurity Secures Another Multiyear Contract to Protect South African Cell Tower Installations
ARIA Cybersecurity Secures Multiyear Contract to Protect Large South African Cell Tower Provider
ARIA Cybersecurity Partners with Oryx Industries to Protect Their Customers Critical Infrastructure Endpoints from Dangerous Cyberattacks
ARIA Cybersecurity Partners with Rexel to Protect Rockwell Automation Customers from Dangerous Cyberattacks
ARIA Cybersecurity Solutions Partners with UFT to Protect Water Treatment Facilities from Dangerous Cyberattacks
ARIA Cybersecurity Solutions Partners with CED to Protect Rockwell Automation Customers from Dangerous Cyberattacks
F500 Electric Energy Producer Selects ARIA AZT PROTECT(TM) to Stop Malicious Cyberattacks
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Addiction Recovery Institute of America ("ARIA") receives Full License for Inpatient Detoxification and Residential Level 1 at its Boca Raton facility